Actuate Therapeutics, Inc. Common stock(ACTU)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.0B
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -9.14% | 2 |
| Feb | -21.63% | 2 |
| Mar | -15.19% | 2 |
| Apr | +15.95% | 2 |
| May | -0.26% | 2 |
| Jun | -27.56% | 2 |
| Jul | +7.52% | 1 |
| Aug | +0.32% | 2 |
| Sep | -24.67% | 2 |
| Oct | +7.01% | 2 |
| Nov | -2.34% | 2 |
| Dec | -10.37% | 2 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 2.23
- Correlation (SPY)
- 30.6%
- R²
- 0.09
- Ann. Volatility
- 89.9%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | AMY L RONNEBERG | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-05-22 | TODD S THOMSON | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-05-22 | Dan Zabrowski | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-05-22 | Roger Sawhney | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-05-22 | Jason A Keyes | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-05-22 | Martin H. Jr. Huber | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-05-22 | Aaron G.L. Fletcher | Director | Grant (A) | +15,000 opt | — | EDGAR | |
| 2026-04-01 | Andrew Paul Mazar | Chief Operating Officer | Grant (A) | +105,000 opt | — | EDGAR | |
| 2026-04-01 | DANIEL M SCHMITT | President, CEO and Director | Grant (A) | +237,000 opt | — | EDGAR | |
| 2026-04-01 | PAUL J LYTLE | Chief Financial Officer | Grant (A) | +105,000 opt | — | EDGAR | |
| 2026-02-13 | DANIEL M SCHMITT | President, CEO and Director | Mixed | +150,181 | $4.33 | -$527.7K | EDGAR |
| 2026-01-07 | Kairos Venture Partners II, L.P. | Director | Sell (S) | −560,000 | $5.80 | -$3.25M | EDGAR |
| 2025-06-30 | Aaron G.L. Fletcher | Director | Buy (P) | +714,280 | $7.00 | $5.00M | EDGAR |
| 2025-06-30 | Bios Equity COF, LP | Director | Buy (P) | +285,712 | $7.00 | $2.00M | EDGAR |
| 2025-06-30 | Bios Equity Partners II, LP | Director | Buy (P) | +714,280 | $7.00 | $5.00M | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | TODD S THOMSON | Director | 1,184,795 | $2.39M | -$750.0K | 3 | 2026-05-22 |
| 2 | Kairos Venture Partners II, L.P. | Director | 873,033 | $1.76M | -$3.25M | 1 | 2026-01-07 |
| 3 | Bios Equity COF, LP | Director | 307,538 | $621.2K | $2.00M | 1 | 2025-06-30 |
| 4 | BIOS Actuate Co-Invest II, LP | Director | 305,457 | $617.0K | $37.75M | 1 | 2024-08-14 |
| 5 | Cavu Management, LP | Director | 195,489 | $394.9K | $37.75M | 1 | 2024-08-14 |
| 6 | DANIEL M SCHMITT | President, CEO and Director | 172,404 | $348.3K | $0 | 4 | 2026-04-01 |
| 7 | BP Directors, LP | Director | 131,248 | $265.1K | $10.73M | 3 | 2024-08-20 |
| 8 | BIOS Capital Management, LP | Director | 131,248 | $265.1K | -$2.00M | 1 | 2024-08-20 |
| 9 | BIOS Fund II, LP | Director | 84,917 | $171.5K | $0 | 1 | 2024-08-14 |
| 10 | Bios Equity Partners II, LP | Director | 69,375 | $140.1K | $3.00M | 2 | 2025-06-30 |
| 11 | BIOS Advisors GP, LLC | Director | 69,375 | $140.1K | $0 | 1 | 2024-08-14 |
| 12 | Aaron G.L. Fletcher | Director | 60,973 | $123.2K | $5.00M | 3 | 2026-05-22 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.